Skip to main content
SpringerLink
Log in
Book cover

Therapeutic Targets of the TNF Superfamily pp 120–129Cite as

4-1BB as a Therapeutic Target for Human Disease

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 647))

Abstract

4-1BB (CD137) is being thought of as an attractive target for immunotherapy of many human immune diseases based on encouraging results with 4-1BB agonistic antibody treatment in mouse models of cancer, autoimmune disease, asthma and additionally as a means to improve vaccination. In this review, we will summarize the results of basic research on 4-1BB and 4-1BB immunotherapy of disease and provide some potential mechanistic insights into the many stimulatory and regulatory functions of 4-1BB.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989; 86:1963.

    Article  PubMed  CAS  Google Scholar 

  2. Schwarz H, Blanco FJ, von Kempis J et al. ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 1996; 87:2839–2845.

    PubMed  CAS  Google Scholar 

  3. Watts TH. TNF/TNFR family members in costimulation of T-cell responses. Annu Rev Immunol 2005; 23:23.

    Article  PubMed  CAS  Google Scholar 

  4. Croft M. Costimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609.

    Article  PubMed  CAS  Google Scholar 

  5. Goodwin RG, Din WS, Davis-Smith T et al. Molecular cloning of a ligand for the inducible T-cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993; 23:2631.

    Article  PubMed  CAS  Google Scholar 

  6. Futagawa T, Akiba H, Kodama T et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14:275.

    Article  PubMed  CAS  Google Scholar 

  7. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 2004; 77:281.

    Article  PubMed  Google Scholar 

  8. Gramaglia I, Cooper D, Miner KT et al. Costimulation of antigen-specific CD4 T-cells by 4-1BB ligand. Eur J Immunol 2000; 30:392.

    Article  PubMed  CAS  Google Scholar 

  9. Cannons JL, Lau P, Ghumman B et al. 4-1BB ligand induces cell division, sustains survival and enhances effector function of CD4 and CD8 T-cells with similar efficacy. J Immunol 2001; 167:1313.

    PubMed  CAS  Google Scholar 

  10. Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T-cell proliferation and lead to the amplification in vivo of cytotoxic T-cell responses. J Exp Med 1997; 186:47.

    Article  PubMed  CAS  Google Scholar 

  11. Bukczynski J, Wen T, Wang C et al. Enhancement of HIV-specific CD8 T-cell responses by dual costimulation with CD80 and CD137L. J Immunol 2005; 175:6378.

    PubMed  CAS  Google Scholar 

  12. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18:558.

    PubMed  CAS  Google Scholar 

  13. Jang IK, Lee ZH, Kim YJ et al. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem Biophys Res Commun 1998; 242:613.

    Article  PubMed  CAS  Google Scholar 

  14. Ma BY, Mikolajczak SA, Danesh A et al. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T-cells. Blood 2005; 106:2002.

    Article  PubMed  CAS  Google Scholar 

  15. Starck L, Scholz C, Dorken B et al. Costimulation by CD137/4-1BB inhibits T-cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005; 35:1257.

    Article  PubMed  Google Scholar 

  16. Lee HW, Park SJ, Choi BK et al. 4-1BB promotes the survival of CD8+ T-lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169:4882.

    PubMed  Google Scholar 

  17. Kwon BS, Hurtado JC, Lee ZH et al. Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 2002; 168:5483.

    PubMed  CAS  Google Scholar 

  18. DeBenedette MA, Wen T, Bachmann MF et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T-cell response to influenza virus. J Immunol 1999; 163:4833.

    PubMed  CAS  Google Scholar 

  19. Shedlock DJ, Whitmire JK, Tan J et al. Role of CD4 T-cell help and costimulation in CD8 T-cell responses during Listeria monocytogenes infection. J Immunol 2003; 170:2053.

    PubMed  CAS  Google Scholar 

  20. Tan JT, Whitmire JK, Ahmed R et al. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T-cell responses. J Immunol 1999; 163:4859.

    PubMed  CAS  Google Scholar 

  21. Bertram EM, Lau P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T-cell numbers late in the primary response and regulates the size of the T-cell memory response following influenza infection. J Immunol 2002; 168:3777.

    PubMed  CAS  Google Scholar 

  22. Bertram EM, Dawicki W, Sedgmen B et al. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T-cell response to influenza in vivo. J Immunol 2004; 172:981.

    PubMed  CAS  Google Scholar 

  23. Dawicki W, Bertram EM, Sharpe AH et al. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004; 173:5944.

    PubMed  CAS  Google Scholar 

  24. Lee SW, Vella AT, Kwon BS et al. Enhanced CD4 T-cell responsiveness in the absence of 4-1BB. J Immunol 2005; 174:6803.

    PubMed  CAS  Google Scholar 

  25. Lee SW, Park Y, Song A et al. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T-cell responses. J Immunol 2006; 177:4464.

    PubMed  CAS  Google Scholar 

  26. Zheng G, Wang B, Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T-cells. J Immunol 2004; 173:2428.

    PubMed  CAS  Google Scholar 

  27. Choi BK, Bae JS, Choi EM et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T-cells. J Leukoc Biol 2004; 75:785.

    Article  PubMed  CAS  Google Scholar 

  28. Irie J, Wu Y, Kachapati K et al. Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 2007; 56:186.

    Article  PubMed  CAS  Google Scholar 

  29. Melero I, Johnston JV, Shufford WW et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167.

    Article  PubMed  CAS  Google Scholar 

  30. Wilcox RA, Tamada K, Strome SE et al. Signaling through NK-cell-associated CD137 promotes both helper function for CD8+ cytolytic T-cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002; 169:4230.

    PubMed  CAS  Google Scholar 

  31. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand J Immunol 2003; 57:305.

    Article  PubMed  CAS  Google Scholar 

  32. Wilcox RA, Chapoval AI, Gorski KS et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002; 168:4262.

    PubMed  CAS  Google Scholar 

  33. Lee SC, Ju SA, Pack HN et al. 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun 2005; 73:5144.

    Article  PubMed  CAS  Google Scholar 

  34. Nishimoto H, Lee SW, Hong H et al. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 2005; 106:4241.

    Article  PubMed  CAS  Google Scholar 

  35. Kim YJ, Li G, Broxmeyer HE. 4-1BB ligand stimulation enhances myeloid dendritic cell maturation from human umbilical cord blood CD34+ progenitor cells. J Hemathother Stem Cell Res 2002; 11:895.

    Article  CAS  Google Scholar 

  36. Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682.

    Article  PubMed  CAS  Google Scholar 

  37. Melero I, Bach N, Hellstrom KE et al. Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 costimulatory pathway. Eur J Immunol 1998; 28:1116.

    Article  PubMed  CAS  Google Scholar 

  38. Guinn BA, DeBenedette MA, Watts TH et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B-cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162:5003.

    PubMed  CAS  Google Scholar 

  39. Wilcox RA, Flies DB, Zhu G et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109:651.

    PubMed  CAS  Google Scholar 

  40. Bansal-Pakala P, Croft M. Defective T-cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 2002; 169:5005.

    PubMed  Google Scholar 

  41. Ye Z, Hellstrom I, Hayden-Ledbetter M et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 2002; 8:343.

    Article  PubMed  CAS  Google Scholar 

  42. Ito F, Li Q, Shreiner AB et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004; 64:8411.

    Article  PubMed  CAS  Google Scholar 

  43. Pan PY, Gu P, Li Q et al. Regulation of dendritic cell function by NK-cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 2004; 172:4779.

    PubMed  CAS  Google Scholar 

  44. Xu DP, Sauter BV, Huang TG et al. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 2005; 12:1526.

    Article  PubMed  CAS  Google Scholar 

  45. Halstead ES, Mueller YM, Altman JD et al. In vivo stimulation of CD137 broadens primary antiviral CD8+ T-cell responses. Nat Immunol 2002; 3:536.

    Article  PubMed  CAS  Google Scholar 

  46. Munks MW, Mourich DV, Mittler RS et al. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004; 112:559.

    Article  PubMed  CAS  Google Scholar 

  47. Arribillaga L, Sarobe P, Arina A et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005; 23:3493.

    Article  PubMed  CAS  Google Scholar 

  48. Harrison JM, Bertram EM, Boyle DB et al. 4-1BBL coexpression enhances HIV-specific CD8 T-cell memory in a poxvirus prime-boost vaccine. Vaccine 2006; 24:6867.

    Article  PubMed  CAS  Google Scholar 

  49. Seo SK, Choi JH, Kim YH et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10:1088.

    Article  PubMed  CAS  Google Scholar 

  50. Fukushima A, Yamaguchi T, Ishida W et al. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 2005; 175:4897.

    PubMed  CAS  Google Scholar 

  51. Sun Y, Lin X, Chen HM et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002; 68:1457.

    Google Scholar 

  52. Sun Y, Chen HM, Subudhi SK et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002; 8:1405.

    Article  PubMed  CAS  Google Scholar 

  53. Foell J, Strahotin S, O’Neil SP et al. CD137 costimulatory T-cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003; 111:1505.

    PubMed  CAS  Google Scholar 

  54. Sun Y, Blink SE, Chen JH et al. Regulation of follicular dendritic cell networks by activated T-cells: the role of CD137 signaling. J Immunol 2005; 175:884.

    PubMed  CAS  Google Scholar 

  55. Mellor AL, Munn DH. IDO expression by dendritic cells:to lerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762.

    Article  PubMed  CAS  Google Scholar 

  56. Cannons JL, Chamberlain G, Howson J et al. Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes. J Autoimmun 2005; 25:13.

    Article  PubMed  CAS  Google Scholar 

  57. Polte T, Foell J, Werner C et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 2006; 116:1025.

    Article  PubMed  CAS  Google Scholar 

  58. Sun Y, Blink SE, Liu W et al. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol 2006; 177:814.

    PubMed  CAS  Google Scholar 

  59. Kim J, Choi WS, La S et al. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T-cells. Blood 2005; 105:2206.

    Article  PubMed  CAS  Google Scholar 

  60. Myers L, Croft M, Kwon BS et al. Peptide-specific CD8 T regulatory cells use IFN-β to elaborate TGF-γ-based suppression. J Immunol 2005; 174:7625.

    PubMed  CAS  Google Scholar 

  61. Lee J, Lee EN, Kim EY et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett 2005; 101:210.

    Article  PubMed  CAS  Google Scholar 

  62. Miller RE, Jones J, Le T et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T-cells in a CD40-dependent manner. J Immunol 2002; 169:1792.

    PubMed  CAS  Google Scholar 

  63. Vinay DS, Kim JD, Kwon BS. Amelioration of mercury-induced autoimmunity by 4-1BB. J Immunol 2006; 177:5708.

    PubMed  CAS  Google Scholar 

  64. Niu L, Strahotin S, Hewes B et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007; 178:4194.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Immunology, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California, 92037, USA

    Seung-Woo Lee & Michael Croft

Authors
  1. Seung-Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Croft
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell, Washington, USA

    Iqbal S. Grewal PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Lee, SW., Croft, M. (2009). 4-1BB as a Therapeutic Target for Human Disease. In: Grewal, I.S. (eds) Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology, vol 647. Springer, New York, NY. https://doi.org/10.1007/978-0-387-89520-8_8

Download citation

Publish with us

Policies and ethics

Search

Navigation